Refractive and visual outcomes with diffractive posterior chamber implantable phakic contact lens (IPCL) for presbyopia treatment: one year follow-up

Session Details

Session Title: Phakic IOLs

Session Date/Time: Sunday 23/09/2018 | 08:00-10:00

Paper Time: 09:32

Venue: Room A3, Podium 1

First Author: : M.Tomita JAPAN

Co Author(s): :                        

Abstract Details

Purpose:

To evaluate refractive and visual outcomes following presbyopia correcting implantable phakic contact lens (IPCL) implantation. IPCL are single piece posterior chamber phakic IOLs, made from hybrid hydrophilic acrylic material. Presbyopia correcting diffractive IPCL interacts with the crystalline lens to enhance patient’s residual accommodation.

Setting:

Minoru Tomita Eye Clinic, Tokyo, Japan

Methods:

This study included 178 eyes of 89 patients who had undergone bilateral implantation of presbyopia correcting implantable phakic contact lens (IPCL; Eyeol, UK). The main outcome measures included uncorrected visual acuity for distance (UDVA) and near (UNVA) (recorded at 30 cm), corrected distance (CDVA) and near (CNVA) and manifest refraction (sphere, cylinder and spherical equivalent (SE)). Patients were examined preoperatively and 1, 3, 6 and 12 months postoperatively.

Results:

Mean age of the subjects was 51 years. At post-operative 1 month, UDVA, UNVA and refraction improved significantly from preoperative values (p<0.05). Preoperatively, the mean SE of -4.0D reduced to -0.21D at 1 month and was found to be stable throughout the follow up period of 12 months. Mean preoperative UDVA was 20/500, which improved to 20/20 at last follow up visit, with no significant change in CDVA. Correspondingly, UNVA improved from J8 to J2 and CNVA remained stable over the 12 months. No intraoperative or postoperative complications were observed.

Conclusions:

Implantation of IPCL for the correction of presbyopia is safe and effective, with good visual and refractive outcomes. Results were found to be stable until the last follow up visit at 12 months.

Financial Disclosure:

-